Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease:: a double blind, placebo controlled, randomised trial

被引:58
|
作者
Wu, JCY [1 ]
Chan, FKL [1 ]
Ching, JYL [1 ]
Leung, WK [1 ]
Hui, Y [1 ]
Leong, R [1 ]
Chung, SCS [1 ]
Sung, JJY [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
关键词
D O I
10.1136/gut.2003.012641
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease (GORD) is controversial. We hypothesised that H pylori eradication leads to worsened control of reflux disease. Methods: Consecutive patients with weekly reflux symptoms were prospectively recruited for endoscopy and symptom evaluation. Patients were enrolled if they had H pylori infection and required long term acid suppressants. Eligible patients were randomly assigned to omeprazole triple therapy (HpE group) or omeprazole with placebo antibiotics (Hp+ group) for one week. Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief. This was followed by a maintenance dose of 10 mg daily for up to 12 months. The primary study end point was the probability of treatment failure within 12 months, which was defined as either incomplete resolution of symptoms or oesophagitis at the initial treatment phase, or relapse of symptoms and oesophagitis during the maintenance phase. Predictors of treatment failure were determined by Cox's proportional hazards model. Results: A total of 236 GORD patients were screened and 113 (47.9%) were positive for H pylori; 104 (92%) patients were included in the intention to treat analysis (53 in the HpE group and 51 in the Hp+ group). Thirty one patients (30%) had erosive oesophagitis at baseline. H pylori was eradicated in 98% of the HpE group and in 3.9% of the Hp+ group. Overall, 15 patients (28.3%) in the HpE group and eight patients (15.7%) in the Hp+ group had treatment failure. The 12 month probability of treatment failure was 43.2% (95% confidence interval (CI) 29.9-56.5%) in the HpE group and 21.1% (95% CI 9.9-32.3%) in the Hp+ group (log rank test, p = 0.043). In the Cox proportional hazards model, after adjustment for the covariates age, sex, erosive oesophagitis, hiatus hernia, degree of gastritis, and severity of symptoms at baseline, H pylori eradication was the only predictor of treatment failure (adjusted hazard ratio 2.47 (95% CI 1.05-5.85)). Conclusion: H pylori eradication leads to more resilient GORD.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [41] Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease:: systematic review
    Raghunath, A
    Hungin, APS
    Wooff, D
    Childs, A
    BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7392): : 737 - 739
  • [42] Helicobacter pylori genotypes and expression of gastritis in erosive gastro-oesophageal reflux disease
    Leodolter, A
    Wolle, K
    Peitz, U
    Ebert, M
    Günther, T
    Kahl, S
    Malfertheiner, P
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2003, 38 (05) : 498 - 502
  • [43] Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus
    Kountouras, Jannis
    Chatzopoulos, Dimitrios
    Zavos, Christos
    MEDICAL HYPOTHESES, 2007, 68 (05) : 1174 - 1175
  • [44] Review article:: Helicobacter pylori and gastro-oesophageal reflux disease -: the European perspective
    McColl, KEL
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 36 - 39
  • [45] Review article:: influence of Helicobacter pylori on gastro-oesophageal reflux disease in Japan
    Haruma, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 40 - 44
  • [46] Helicobacter pylori and gastro-oesophageal reflux disease -: Important data were not presented
    Beales, ILP
    BRITISH MEDICAL JOURNAL, 2004, 329 (7462): : 402 - 402
  • [47] Carditis:: All Helicobacter pylori or is there a role for gastro-oesophageal reflux?
    McNamara, D
    Buckley, M
    Crotty, P
    Hall, W
    O'Sullivan, M
    O'Morain, C
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (07) : 772 - 777
  • [48] Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole
    Kiljander, TO
    Salomaa, ERM
    Hietanen, EK
    Terho, EO
    EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) : 633 - 638
  • [49] Relationship between intestinal metaplasia of the gastro-oesophageal junction, Helicobacter pylori infection and gastro-oesophageal reflux disease:: a prospective study
    Pieramico, O
    Zanetti, MV
    DIGESTIVE AND LIVER DISEASE, 2000, 32 (07) : 567 - 572
  • [50] Prevalence of symptomatic gastro-oesophageal reflux disease in Japanese patients with peptic ulcer disease after eradication of Helicobacter pylori infection
    Yamamori, K
    Fujiwara, Y
    Shiba, M
    Watanabe, T
    Tominaga, K
    Oshitani, N
    Matsumoto, T
    Higuchi, K
    Arakawa, T
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 107 - 111